Novartis secured regulatory approvals in Switzerland for Coartem Baby, a novel formulation of its malaria combination therapy designed for newborns and infants. This approval addresses an unmet medical need for this vulnerable population and Novartis plans to distribute the drug largely at cost in affected regions. The move positions Novartis as the first company with an approved malaria treatment for the youngest patients.